palbociclib

Novartis edges closer to market, rival Ibrance with latest PhIII data update

Novartis is closing in on becoming the second Big Pharma to market in the major blockbuster CDK 4/6 space--after rival Pfizer--with positive late-stage survival data posted at the ESMO cancer conference this weekend.

Ben Adams Oct 10, 2016 3:58am